Beren Therapeutics P.B.C.

Beren Therapeutics P.B.C. is a founder-led, clinical-stage biotechnology company and public benefit corporation focused on developing cyclodextrin-based therapeutics for conditions characterized by impaired intracellular cholesterol trafficking, including Niemann-Pick disease type C (NPC) and other neurodegenerative conditions. Through its subsidiary Mandos LLC, Beren is advancing adrabetadex for individuals living with NPC, an ultra-rare genetic disease affecting the brain and other organ systems. Founded in 2020 by Jason Camm, former Managing Director and CMO of Thiel Capital, Beren has built a fully integrated organization spanning discovery through commercialization, with $300M in financing secured in 2026 toward a potential commercial launch.